Artificial intelligence (AI) isn't the only industry with explosive growth potential.

The business may not be as strong as its performance this year suggests.

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market. | Immunology biotech ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

Arcellx Inc. (NASDAQ:ACLX) is one of the best high short interest stocks with biggest upside potential. On January 7, UBS ...

Cantai launched in 2023 with a $3 million seed round. The company has raised $6.55 million to date at an undisclosed valuation, according to PitchBook. It develops drug candidates with special ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

Venture capitalists point to a surge in M&A and a glint of revival in the IPO arena as signs of better days ahead.

UK biotech showed resilience in a tough 2025 for healthcare funding, suggesting investor interest could grow in 2026.

Choose Pittsburgh Business Times as a preferred news source to see more of our reporting on Google. Del Brady co-founded ...